Molecular mechanisms of hepatocellular carcinoma
- PMID: 19003900
- DOI: 10.1002/hep.22580
Molecular mechanisms of hepatocellular carcinoma
Abstract
Hepatocellular carcinoma (HCC) typically has poor prognosis, because it is often diagnosed at an advanced stage. Heterogeneous phenotypic and genetic traits of affected individuals and a wide range of risk factors have classified it a complex disease. HCC is not amenable to standard chemotherapy and is resistant to radiotherapy. In most cases, surgical resection and liver transplantation remain the only curative treatment options. Therefore, development of novel, effective therapies is of prime importance. Extensive research over the past decade has identified a number of molecular biomarkers as well as cellular networks and signaling pathways affected in liver cancer. Recent studies using a combination of "omics" technologies, microRNA studies, combinatorial chemistry, and bioinformatics are providing new insights into the gene expression and protein profiles during various stages of the disease. In this review, we discuss the contribution of these newer approaches toward an understanding of molecular mechanisms of HCC and for the development of novel cancer therapeutics.
Similar articles
-
New therapies for hepatocellular carcinoma.Oncogene. 2006 Jun 26;25(27):3866-84. doi: 10.1038/sj.onc.1209550. Oncogene. 2006. PMID: 16799628 Review.
-
Human hepatocellular carcinoma: expression profiles-based molecular interpretations and clinical applications.Cancer Lett. 2009 Dec 1;286(1):96-102. doi: 10.1016/j.canlet.2008.11.005. Epub 2008 Dec 17. Cancer Lett. 2009. PMID: 19095350 Review.
-
New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system.Liver Int. 2007 Mar;27(2):174-85. doi: 10.1111/j.1478-3231.2006.01424.x. Liver Int. 2007. PMID: 17311611 Review.
-
Genetic profiling of human hepatocellular carcinoma.Semin Liver Dis. 2005;25(2):125-32. doi: 10.1055/s-2005-871192. Semin Liver Dis. 2005. PMID: 15918141 Review.
-
Treatment options for hepatocellular carcinoma.Expert Rev Gastroenterol Hepatol. 2008 Feb;2(1):81-92. doi: 10.1586/17474124.2.1.81. Expert Rev Gastroenterol Hepatol. 2008. PMID: 19072372 Review.
Cited by
-
Bioinformatics analysis reveals potential candidate drugs for HCC.Pathol Oncol Res. 2013 Apr;19(2):251-8. doi: 10.1007/s12253-012-9576-y. Epub 2013 Jan 23. Pathol Oncol Res. 2013. PMID: 23341104
-
Novel roles of TMEM100: inhibition metastasis and proliferation of hepatocellular carcinoma.Oncotarget. 2015 Jul 10;6(19):17379-90. doi: 10.18632/oncotarget.3954. Oncotarget. 2015. PMID: 25978032 Free PMC article.
-
Hydroxysteroid sulfotransferase SULT2B1b promotes hepatocellular carcinoma cells proliferation in vitro and in vivo.PLoS One. 2013 Apr 11;8(4):e60853. doi: 10.1371/journal.pone.0060853. Print 2013. PLoS One. 2013. PMID: 23593328 Free PMC article.
-
Current Research Progress on Long Noncoding RNAs Associated with Hepatocellular Carcinoma.Anal Cell Pathol (Amst). 2019 Jun 24;2019:1534607. doi: 10.1155/2019/1534607. eCollection 2019. Anal Cell Pathol (Amst). 2019. PMID: 31341758 Free PMC article. Review.
-
IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma.Med Sci Monit. 2014 Feb 14;20:247-54. doi: 10.12659/MSM.889891. Med Sci Monit. 2014. PMID: 24531386 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous